Table 4.
Guideline Recommendations for Recommended Topics of Discussion Between Physician and Patient, By Guideline Source and Year of Publication
| Topic | AAP (2008)13 | COSA (2011)17 | NICE (2013)22 | SIGN (2013)25 | ASCO (2013)15 |
|---|---|---|---|---|---|
| Fertility will be affected by treatment | Yes | Yes | Yes | Yes | Yes |
| Give written information | Not discussed | Yes | Yes | Yes | Not discussed |
| Offer fertility counseling and psychological support | Yes in moderately distressed people | Yes | Not discussed | Yes | Yes |
| Who should discuss fertility preservation methods? | Oncologist or fertility specialist | Oncologist or fertility specialist | Fertility specialist | Fertility specialist | Healthcare providers or fertility specialist |
| No known risk of genetic abnormalities in offspring | Yes | Not discussed | Not discussed | Yes | Yes |
| No known increased risk of recurrent disease associated with fertility preservation methods | Yes | Not discussed | Not discussed | Not discussed | Yes |
| Manage subsequent pregnancy as high-risk | Not discussed | Yes | Not discussed | Yes | Yes |
| Ownership/destruction of stored gametes if patients dies | Yes | Not discussed | Not discussed | Not discussed | Not discussed |
AAP, American Academy of Pediatrics; ASCO, American Society of Clinical Oncology; COSA, Clinical Oncological Society of Australia; NICE, the National Institute for Health and Clinical Excellence; SIGN, Scottish Intercollegiate Guidelines Network.